Vantage Consulting Group Inc - Q4 2021 holdings

$372 Million is the total value of Vantage Consulting Group Inc's 231 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .

 Value Shares↓ Weighting
ADCT  ADC THERAPEUTICS SA SHS$33,939,000
-25.6%
1,680,1490.0%9.12%
-6.6%
ITCI  Intra-Cellular Therapies, Inc.$11,864,000
+40.4%
226,6700.0%3.19%
+76.2%
FGEN  Fibrogen, Inc$8,541,000
+38.0%
605,7130.0%2.30%
+73.2%
VFC  V.F. Corporation$266,000
+9.5%
3,6330.0%0.07%
+38.5%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ROYALTY PHARMA PLC12Q3 202387.5%
ADC THERAPEUTICS SA SHS12Q3 20239.8%
FIBROGEN INC12Q3 20235.7%
COSTCO WHSL CORP NEW12Q3 20230.5%
WALMART INC12Q3 20230.5%
Sysco Corporation12Q3 20230.5%
Exxon Mobil Corporation12Q3 20230.5%
Chevron Corporation12Q3 20230.5%
KROGER CO12Q3 20230.5%
CVS Health Corporation12Q3 20230.5%

View Vantage Consulting Group Inc's complete holdings history.

Latest significant ownerships (13-D/G)
Vantage Consulting Group Inc Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
SYNTAX ETF TRUSTSeptember 11, 2023717,13252.2%
SYNTAX ETF TRUSTNovember 08, 2022156,13356.8%
SYNTAX ETF TRUSTSold outJune 24, 2021012.4%

View Vantage Consulting Group Inc's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
SC 13G/A2023-09-11
13F-HR2023-08-11
13F-HR2023-05-10
13F-HR2023-02-13
13F-HR2022-11-14
SC 13G/A2022-11-08
SC 13G/A2022-10-04
SC 13G/A2022-09-12

View Vantage Consulting Group Inc's complete filings history.

Compare quarters

Export Vantage Consulting Group Inc's holdings